Skip to main content

Table 1 Patient and clinical characteristics (no. of patients (%))

From: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

 

All (N=45)

Pancreatic (N=19)

Gastrointestinal intestinal and unknown origin (N=17)

Others lung and paraganglioma (N=9)

Sex

    

Male

32 (71.1)

15 (78.9)

9 (52.9)

8 (88.9)

Female

13 (28.9)

4 (21.1)

8 (47.1)

1 (11.1)

Age (yrs)

    

Median (range)

52 (28-73)

   

ECOG performance status

    

0

36 (80.0)

13 (68.4)

17 (100)

6 (66.7)

1

6 (13.3)

3 (15.8)

--

3 (33.3)

2

3 (6.7)

3 (15.8)

  

Ki67 index

    

≤2

10 (25.6)

2 (11.8)

5 (33.3)

3 (42.8)

3-20

29 (74.4)

15 (88.2)

15 (66.6)

4 (57.2)

Missing

6

2

2

2

Octreoscan

    

Positive

43 (95.6)

18 (94.7)

16 (94.1)

9 (100)

Negative

2 (4.4)

1 (5.3)

1 (5.9)

 

Circulating chromogranin A

    

Normal

8

3 (17.6)

4 (23.5)

1 (12.5)

Elevated

34

14 (82.4)

13 (76.5)

7 (87.5)

Missing

3

2

--

1

Sites of metastatic disease

    

Liver

41 (91.1)

18 (94.7)

16 (94.1)

7 (77.8)

Lymph nodes

17 (37.8)

6 (31.4)

8 (47.1)

3 (33.3)

Lung

5 (11.1)

0 (0)

--

4 (44.4)

Bone

2 (4.4)

2 (10.5)

1 (5.9)

--

Syndrome

17 (37.8)

5 (26.3)

11 (64.7)

1 (11.1)

Diarrhea

10 (22.2)

3 (15.8)

6 (35.3)

1 (11.1)

Hot flashes

7 (15.6)

--

6 (35.3)

1 (11.1)

Rash

7 (15.6)

--

6 (35.3)

1 (11.1)

Hypoglycemia

1 (2.2)

1 (5.3)

--

--

Cushing’s syndrome

1 (2.2)

1 (5.3)

--

--

Previous treatments

    

Surgery

34 (75.6)

13 (68.4)

14 (82.3)

7 (77.8)

Radiotherapy

2 (4.4)

2 (10.5)

--

--

Radionuclide therapy with somatostatin analogues

23 (51.1)

10 (43.5)

8 (34.8)

5 (21.7)